AlbaJuna Therapeutics,

AlbaJuna Therapeutics is the result of the agreement between IrsiCaixa, Grifols corporation and the researchers Bonaventura Clotet, Jorge Carrillo and Julià Blanco.  The spin-off is  developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the “natural killer” cells responsible for destroying cells infected by the virus.